Key Takeaways

  • Orforglipron cut AHI by 13.2 and 12.0 events/hour more than placebo in two 52-week trials
  • Patients also lost about 10% of body weight; stomach side effects were common
  • The pill is not approved for sleep apnea anywhere — Lilly plans an FDA filing by end of 2026

Could a daily pill do part of what a mask does?

For people with obstructive sleep apnea (OSA) who cannot tolerate a CPAP mask, treatment options have been thin. Two phase 3 trials published in JAMA on November 9, 2026 — the ATTAIN-OSA trials — tested whether Eli Lilly's once-daily oral GLP-1 pill, orforglipron, could reduce the severity of the condition itself.

Together the trials randomized 712 adults with moderate-to-severe OSA (an apnea-hypopnea index, or AHI, of at least 15 events per hour) and a BMI of at least 27. One trial (363 people) enrolled patients not using PAP therapy; the other (349) enrolled patients on PAP, with AHI measured after a week off it. Treatment lasted 52 weeks. Participants' apnea was severe at the start — average AHI of about 51 and 58 events per hour.

The headline numbers

Using the trials' primary analysis:

  • No-PAP trial: AHI fell by 17.8 events/hour on orforglipron vs 4.5 on placebo — a difference of 13.2 events/hour (P < .001).
  • PAP trial: AHI fell by 17.3 vs 5.3 — a difference of 12.0 events/hour (P < .001).
  • Weight: patients on the pill lost 10.4% and 10.7% of body weight, vs about 1-2% on placebo.
  • More patients on the drug achieved at least a 50% AHI reduction (between-group differences of 26.1 and 17.7 percentage points) or reached remission or mild disease.

One caution on numbers you may see elsewhere: Lilly's press release reports larger AHI reductions (up to about 44%) using a different statistical estimand that assumes everyone stayed on treatment. The figures above are the journal's primary analysis.

The honest limits

  • Stomach side effects were common: about 68-71% of patients on orforglipron had a gastrointestinal event (nausea, diarrhea, constipation, indigestion, vomiting), vs about 37% on placebo; most were mild to moderate. More patients stopped the drug because of side effects — 12.2% vs 3.8% in one trial, 6.8% vs 0.6% in the other.
  • One of seven key secondary endpoints missed: patient-reported sleep impairment improved but was not statistically significant under the primary analysis (P = .07).
  • Who was studied: mostly severe OSA; people with diabetes, BMI under 27, or mild apnea were excluded, and racial and ethnic diversity was low. Outcomes beyond 52 weeks were not evaluated, and no minimum clinically important difference has been defined for AHI — the trials measured a breathing index, not heart outcomes.
  • The trials were funded by Eli Lilly, which was involved in design, analysis and writing support; the lead author reported personal fees from Lilly.

Not an approved apnea treatment — yet

Orforglipron (brand name Foundayo) is approved in the United States for weight management, but it is not approved for sleep apnea anywhere. Lilly says it plans to submit it to the US FDA for moderate-to-severe OSA by the end of 2026. An injectable drug, tirzepatide, is already approved for this use — orforglipron would be the first oral option.

Health note: This article reports trial results and is not medical advice. Sleep apnea treatment decisions — including whether medication is appropriate — belong with your own doctor, who knows your health history.

The Twikup Take

The results are genuinely promising: a pill taken once a day, with no mask, cut breathing interruptions substantially and took off about a tenth of body weight. But read them as the journal presents them, not the press release — the benefit is real but more modest, the stomach side effects are the price most users will feel, and approval for apnea is still a filing away.

Image: Illustrative image.

Sources